Assessing physician and patient acceptance of infliximab biosimilars in rheumatoid arthritis, ankylosing spondyloarthritis and psoriatic arthritis across Germany

References

• Expert Committee on Biological Standardization [webpage on the Internet]Guidelines on Evaluation of Similar Biotherapeutic Products (SBPs)GenevaWorld Health Organisation2009134 Available from: http://www.who.int/biologicals/areas/biological_therapeuticsAccessed July 29, 2016
   Google Scholar
• Committee for Medicinal Products for Human Use (CHMP)Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issuesLondon2012 cited July 29, 201619 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/06/WC500167838.pdfAccessed March 2, 2017
   Google Scholar
• US Food and Drug AdministrationQuality Considerations in Demonstrating Biosimilarity to a Reference Product: Draft Guidance2012 Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291134.pdfAccessed July 29, 2016
   Google Scholar
• BeckAReichertJMApproval of the first biosimilar antibodies in EuropemAbs20135562162323924791
   PubMed Web of Science ®Google Scholar
• McKee S [webpage on the Internet]Hospira launches Remicade biosimilar in major EU markets2015 Available from: http://www.pharmatimes.com/news/hospira_launches_remicade_biosimilar_in_major_eu_markets_971052Accessed August 12, 2016
   Google Scholar
• Hernandez R [webpage on the Internet]Celltrion Launches Remicade Biosimilar in European Markets Available from: http://www.biophar-minternational.com/celltrion-launches-remicade-biosimilar-european-marketsAccessed August 12, 2016
   Google Scholar
• Generics and Biosimilars Initiative [webpage on the Internet]Use of biosimilars in Europe differs across countries GaBOnline2014 [cited July 11, 2016]. Available from: http://www.gabionline.net/Reports/Use-of-biosimilars-in-Europe-differs-across-countriesAccessed July 11, 2016
   Google Scholar
• NiederwieserDSchmitzSBiosimilar agents in oncology/haematology: from approval to practiceEur J Haematol201186427728821175852
   PubMed Web of Science ®Google Scholar
• Regulation RahmenvertragGerman Bundesministerium der Justiz German Social Law Book ‘Aut idem’§ 129;2008 p section 4 sentence 1. Available from: http://www.gesetze-im-internet.de/sgb_5/__129.htmlAccessed March 2, 2017
   Google Scholar
• GaBI Online – Generics and Biosimilars Initiative [webpage on the Internet]UK biosimilars uptake lower than in some other EU countries Available from: http://gabionline.net/Reports/UK-biosimilars-uptake-lower-than-in-some-other-EU-countriesAccessed August 12, 2016
   Google Scholar
• RoviraJEspínJGarcíaLOlry de LabryAThe impact of biosimilars’ entry in the EU market Report prepared for the European Commission (Directorate-General for Enterprise and Industry)BrusselsEuropean Commission2011 Available from: http://ec.europa.eu/DocsRoom/documents/7651/attachments/1/translations/en/renditions/pdfAccessed October 3, 2016
   Google Scholar
• WeiseMKurkiPWolff-HolzEBielskyM-CSchneiderCKBiosimilars: the science of extrapolationBlood2014124223191319625298038
   PubMed Web of Science ®Google Scholar
• ZelenetzADAhmedIBraudELNCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectivesJ Natl Compr Cancer Netw20119suppl 4S1S22
   PubMed Web of Science ®Google Scholar
• AaproMSWhat do prescribers think of biosimilars?Target Oncol20127suppl 1S51S5522258706
   PubMed Web of Science ®Google Scholar
• DolinarROReillyMSBiosimilars naming, label transparency and authority of choice – survey findings among European physiciansGenerics Biosimilars Initiat J2014325862
   Google Scholar
• BajiPGulácsiLLovászBDTreatment preferences of originator versus biosimilar drugs in Crohn’s disease; discrete choice experiment among gastroenterologistsScand J Gastroenterol2016511222726059967
   PubMed Web of Science ®Google Scholar
• BajiPGulácsiLGolovicsPAPerceived risks contra benefits of using biosimilar drugs in ulcerative colitis: discrete choice experiment among gastroenterologistsValue Health Reg Issues201610859027881284
   PubMedGoogle Scholar
• NarayananSRelationship between the duration of rheumatology practice experience and likelihood of use and perception towards biosimilars in rheumatoid arthritis arenaAnn Rheum Dis201473suppl 262462424257024
   PubMed Web of Science ®Google Scholar
• Decision Resources Group [webpage on the Internet]German Rheumatologists and Gastroenterologists Say They Are Not Under Pressure to Switch Patients on Remicade to Infliximab Biosimilars2015 Available from: http://www.prnewswire.com/news-releases/german-rheumatologists-and-gastroenterologists-say-they-are-not-under-pressure-to-switch-patients-on-remicade-to-infliximab-biosimilars-300145025.htmlAccessed March 2, 2017
   Google Scholar
• NotaIDrossaertCHCTaalEVonkemanHEvan de LaarMAPatient participation in decisions about disease modifying anti-rheumatic drugs: a cross-sectional surveyBMC Musculoskelet Disord20141533325281209
   PubMed Web of Science ®Google Scholar
• ZangiHANdosiMAdamsJEuropean League Against Rheumatism (EULAR)EULAR recommendations for patient education for people with inflammatory arthritisAnn Rheum Dis201574695496225735643
   PubMed Web of Science ®Google Scholar
• CaseyDKey strategic factors for stakeholders in the current global biosimilar marketDrug Discov Today201621220821126375407
   PubMed Web of Science ®Google Scholar
• JacobsISinghESewellKLAl-SabbaghAShaneLGPatient attitudes and understanding about biosimilars: an international cross-sectional surveyPatient Prefer Adherence20161093794827307714
   PubMed Web of Science ®Google Scholar
• European Medicine AgencySummary of the risk management plan (RMP) for Benepali (etanercept)EMA201513 Report No: EMA/783235/2015. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Risk-management-plan_summary/human/004007/WC500196679.pdfAccessed August 12, 2016
   Google Scholar
• Generics and Biosimilars Initiative [webpage on the Internet]Biosimilars of adalimumab2014 Available from: http://www.gabion-line.net/Biosimilars/General/Biosimilars-of-adalimumabAccessed August 12, 2016
   Google Scholar
• Pfenex [webpage on the Internet]Pfenex, Biosimilars, and Better Health2015 Available from: http://www.pfenex.com/the-pfenex-difference/Accessed August 12, 2016
   Google Scholar
• Investor Overview – InvestorsEPIRUS Biopharmaceuticals, Inc. Available from: http://ir.epirusbiopharma.com/Accessed August 12, 2016
   Google Scholar
• Novartis [webpage on the Internet]Sandoz’ biosimilar rituximab regulatory submission accepted by European Medicines AgencyNovartis Available from: https://www.novartis.com/news/media-releases/sandoz-biosimilar-rituximab-regulatory-submission-accepted-european-medicinesAccessed August 12, 2016
   Google Scholar
• AndersonPBenfordMHarrisNKaravaliMPiercyJReal-world physician and patient behaviour across countries: Disease-Specific Programmes – a means to understandCurr Med Res Opin200824113063307218826746
   PubMed Web of Science ®Google Scholar
• European Pharmaceutical Market Research Association [webpage on the Internet]European Pharmaceutical Market Research Association – Code of ConductEphMRA Available from: http://www.ephmra.org/Code-of-Conduct-SupportAccessed January 19, 2017
   Google Scholar
• IMSDelivering on the Potential of Biosimilar Medicines the Role of Functioning Competitive Markets2016140 Available from: https://www.imshealth.com/files/web/IMSH%20Institute/Healthcare%20Briefs/Documents/IMS_Institute_Biosimilar_Brief_March_2016.pdfAccessed August 12, 2016
   Google Scholar
• CortinovisDBerettaGPiazzaEAIOM LombardiaChemotherapy-induced anemia and oncologist perception on treatment: results of a web-based surveyTumori2013991455023548999
   PubMed Web of Science ®Google Scholar
• WilkinsARVenkatMVBrownASPatient perspectives on biosimilar insulinJ Diabetes Sci Technol201481232524876533
   PubMedGoogle Scholar
• PutrikPRamiroSKvienTKWorking Group ‘Equity in access to treatment of rheumatoid arthritis in Europe’Inequities in access to biologic and synthetic DMARDs across 46 European countriesAnn Rheum Dis201473119820623467636
   PubMed Web of Science ®Google Scholar
• Rak TkaczukKHJacobsIABiosimilars in oncology: from development to clinical practiceSemin Oncol201441suppl 3S3S12
   PubMed Web of Science ®Google Scholar
• MoorkensEJonker-ExlerCHuysIDeclerckPSimoensSVultoAGOvercoming barriers to the market access of biosimilars in the European Union: the case of biosimilar monoclonal antibodiesFront Pharmacol2016719327445826
   PubMed Web of Science ®Google Scholar
• PutrikPRamiroSLieELess educated and older patients have reduced access to biologic DMARDs even in a country with highly developed social welfare (Norway): results from Norwegian cohort study NOR-DMARDRheumatology (Oxford)20165571217122427012686
   PubMed Web of Science ®Google Scholar
• PutrikPRamiroSKvienTKSokkaTUhligTBoonenAVariations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country’s wealth?Ann Rheum Dis201473112010202123940213
   PubMed Web of Science ®Google Scholar